Latest Intellectual Property News

Argo Investments reports a robust half-year profit of $121.2 million and announces a record fully franked interim dividend of 17.0 cents per share, driven by increased dividend revenue and strategic portfolio moves.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

iCandy Interactive reports a remarkable 105% increase in net cash flow for Q4 2024 despite a 22% drop in cash receipts, driven by strategic expansions and operational efficiencies amid ongoing legal disputes.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Wide Open Agriculture reports a 50% reduction in overheads alongside the development of a novel lupin-based tofu product, positioning itself for growth in the global plant protein market.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.